Michelle Yeagley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michelle Yeagley has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Blake M. Callahan
Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA
1 shared publicationBoris I. Chobrutskiy
Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA
1 shared publication- Dhruv N. Patel
College of Osteopathic Medicine, Nova Southeastern University, Fl, EE. UU
1 shared publication - Etienne C. Gozlan
Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA
1 shared publication - George Blanck
University of South Florida
1 shared publication Nikhila Medikonda
Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA
1 shared publication
Latest Publications
- 22 February 2021
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 38 (3) , 251-264
Electrostatic Complementarity of T-Cell Receptor-Alpha CDR3 Domains and Mutant Amino Acids Is Associated with Better Survival Rates for Sarcomas
While sarcoma immunology has advanced with regard to basic, and even some applied topics, this disease has not been subject to more recent immunogenomics approaches. Thus, we assessed the immune receptor recombinations available from the cancer genome atlas (TCGA) sarcoma database via tumor sample exome and RNASeq files. Results indicated that recovery of T-cell receptor-alpha recombination reads (TRA) correlated with a better survival rate, with the expression of T-cell biomarkers, and with tumor sample apoptosis signatures consistent with the longer patient survival times. Furthermore, samples representing TRA complementarity determining region-3 (CDR3) net charge per residue (NCPR) based complementarity with the corresponding sarcoma mutanome had a better survival rate, and more granzyme expression, than samples lacking such complementarity. By specifically using RNASeq-recovered TRA CDR3s and related NCPR assessments, three genes, TP53, ATRX, and RB1, were identified as being key components of the mutanome-based complementarity. Thus, these genes may represent key immune system targets for soft tissue sarcomas. Also, several key results from above were reproduced with a pediatric osteosarcoma dataset, work that led to identification of MUC6 mutations as potentially linked to a strong immune response. In sum, TRA CDR3s are likely to be important prognostic indicators, and possibly a beginning tool for immunotherapy development strategies, for adult and pediatric sarcomas.
- 22 February 2021
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 38 (3) , 251-264
Electrostatic Complementarity of T-Cell Receptor-Alpha CDR3 Domains and Mutant Amino Acids Is Associated with Better Survival Rates for Sarcomas
While sarcoma immunology has advanced with regard to basic, and even some applied topics, this disease has not been subject to more recent immunogenomics approaches. Thus, we assessed the immune receptor recombinations available from the cancer genome atlas (TCGA) sarcoma database via tumor sample exome and RNASeq files. Results indicated that recovery of T-cell receptor-alpha recombination reads (TRA) correlated with a better survival rate, with the expression of T-cell biomarkers, and with tumor sample apoptosis signatures consistent with the longer patient survival times. Furthermore, samples representing TRA complementarity determining region-3 (CDR3) net charge per residue (NCPR) based complementarity with the corresponding sarcoma mutanome had a better survival rate, and more granzyme expression, than samples lacking such complementarity. By specifically using RNASeq-recovered TRA CDR3s and related NCPR assessments, three genes, TP53, ATRX, and RB1, were identified as being key components of the mutanome-based complementarity. Thus, these genes may represent key immune system targets for soft tissue sarcomas. Also, several key results from above were reproduced with a pediatric osteosarcoma dataset, work that led to identification of MUC6 mutations as potentially linked to a strong immune response. In sum, TRA CDR3s are likely to be important prognostic indicators, and possibly a beginning tool for immunotherapy development strategies, for adult and pediatric sarcomas.